Pipeline

Pipeline

Focusing on niche markets with high medical needs, SymBio continues to in-license new drug candidates with confirmed POC (Proof of Concept) in human subjects from bio-ventures and pharmaceutical companies worldwide, aiming to shorten the development timeline to commercialization. SymBio will continue to proactively expand indications of existing products and introduce promising new drug candidates to build a robust product pipeline.

[TREAKISYM®] Treakisym SyB L-0501 SyB L-0501
[Rigosertib] Rigosertib Sodium SyB L-1101 SyB C-1101 SyB L-1101/SyB C-1101
SyB C-1101 SyB L-1101 SyB L-1101 SyB C-1101
[Brincidofovir] Brincidofovir SyB V-1901 SyB V-1901

※1 NDA : New Drug Application
※2 MA : Marketing Approval